ModifiedUnitedHealthcarePolicy 2026T0561X

Electrical and Ultrasonic Bone Growth Stimulators

Policy governing use and coverage criteria for invasive and noninvasive electrical bone growth stimulators and low-intensity ultrasonic bone growth stimulators for UnitedHealthcare Commercial and Individual Exchange members.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical and Ultrasonic Bone Growth Stimulators

Policy CodePolicy 2026T0561X

Change TypeRevised criteria and added documentation requirements

Effective DateFeb 1, 2026

Next Review Date

Key ActionSubmit required medical records including condition, relevant imaging, surgical history with dates, physician treatment plan, and prior treatments tried/failed when requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

Revised coverage criteria for Ultrasonic Bone Growth Stimulators; replaced criterion requiring 'less than 6 months have passed since the date of most recent surgical operation' with 'less than 6 months have passed since the date of most recent surgical procedure'.

Added language to clarify the use of an Invasive or Non-Invasive Electrical Bone Growth Stimulator is unproven and not medically necessary for the treatment of all other indications (including stress fractures).

Added required documentation elements for medical records review for Electrical Bone Growth Stimulators (condition requiring procedure; detailed relevant imaging including evidence of skeletal maturity and spondylolisthesis presence/absence and grade; physician's treatment plan).

Clarified wording for comorbid conditions and for history of previous spinal fusion surgery(s) documentation.

2distinct device types with coverage statements

6ultrasound nonunion criteria items

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Electrical Bone Growth Stimulators — Spinal Fusion (Adjunct)

Covered when ALL of the following are met:

Spinal EBGS coverage: Radiographic evidence of skeletal maturity

Increased risk for fusion failure: Any one of: previously failed fusion at the same site (minimum of six months elapsed since the last surgical procedure); spinal fusion performed or to be performed at more than one level as part of a single surgery; comorbid conditions associated with compromised bone healing (e.g., diabetes, obesity, osteoporosis, current tobacco use); spondylolisthesis grade II or greater

Previously failed fusion requires minimum 6 months elapsed since the last surgical procedure

Ultrasonic Bone Growth Stimulators — Long Bone Nonunion

Covered when ALL of the following are met:

Ultrasound nonunion coverage: Fracture gap is less than or equal to 1 cm<= 1 cm

Ultrasound nonunion coverage: Radiographic evidence of a persistent fracture line without bridging callus present for 3 months or more>= 3 months

Ultrasound nonunion coverage: Fracture reduced and immobilized

Ultrasound nonunion coverage: Less than 6 months have passed since the date of most recent surgical procedure< 6 months

Ultrasound nonunion coverage: Fracture is not pathological or associated with malignancy

Ultrasound nonunion coverage: Radiographic evidence of skeletal maturity

Not Medically Necessary / Unproven Indications

Unproven EBGS: Use of invasive or non-invasive electrical bone growth stimulators for all other indications (including stress fractures) is unproven and not medically necessary due to insufficient evidence of efficacy and/or safety

Unproven Ultrasound: Use of ultrasonic bone growth stimulators for all other indications (including stress fractures) is unproven and not medically necessary due to insufficient evidence of efficacy and/or safety

Electrical stimulation for spinal fusion (NASS)

Electrical stimulation for spinal fusion healing is indicated when ALL of the following apply in patients at high risk for pseudarthrosis:

NASS spinal fusion augmentation criteria: Patient is undergoing augmentation of spinal fusion in any spinal region AND patient meets high-risk criteria (see High-Risk Criteria) AND either is undergoing fusion of 2 or more motion segments OR is undergoing revision spinal fusion OR is a smoker who cannot stop OR has qualifying comorbidities (diabetes; inflammatory arthritis requiring long-term corticosteroids; immunocompromised state; systemic vascular disease; osteopenia/osteoporosis)

Applies to augmentation of spinal fusion per NASS 2025 guidance

Electrical stimulation for acute traumatic spinal fracture (conditional)

Conditionally recommended adjunct for primary bone healing of acute traumatic spinal fractures in high-risk patients for pseudarthrosis for up to 6 months followed by CT to assess union when ALL of the following apply:

Acute spinal fracture eligibility: Acute traumatic spinal fracture as defined (compression/burst fractures with ≥50% vertebral height loss, associated segmental angulation 5–15°, associated stable translational deformity on dynamic imaging) OR acute symptomatic spondylolysis without neurologic compression OR acute nontraumatic osteoporotic compression fractures with significant pain >6 weeks without neurologic deficits and without pathologic fracture; AND patient exhibits one or more high-risk criteria6 months follow-up with CT imaging to establish osseous union

Conditional recommendation per NASS; dynamic imaging should fail to show translational displacement >2 mm or focal segmental angulation >5° before deeming nonunion

Ultrasonic bone growth stimulators (nonunion)

Ultrasonic (LIPUS) stimulators — coverage stance derived from evidence synthesis:

LIPUS for long-bone nonunion: Systematic reviews and case series suggest benefit for treatment of long-bone nonunions with pooled heal rates around 82–84% in selected studies; greater likelihood of success when used as an alternative to surgery, with small gap size (<1 cm) and shorter interval since prior surgeryfracture age >= 3 months (stricter nonunion definitions may use >= 8 months)

Evidence limited by study heterogeneity; guidelines (NICE) recommend restricted use or research settings for many indications

Electrical stimulation is not indicated for routine primary (index) spinal fusions in patients who do not have additional risk factors for fusion failure. Per NASS guidance and the policy, stimulators are intended as an adjunct when the member is at high risk for pseudarthrosis (for example, revision fusion, multilevel fusion, active tobacco use that cannot be stopped, or comorbidities that impair bone healing). Primary single‑segment fusions without those qualifying risk factors should not be treated with electrical stimulators.

The policy therefore restricts coverage of electrical bone growth stimulators for spinal fusion to patients who meet the documented high‑risk criteria and radiographic evidence of skeletal maturity; use for first‑attempt fusions without those risk factors is excluded as not indicated.

Indications for electrical and ultrasonic stimulators are limited to the specific scenarios outlined in the policy; documentation must support the indication. For electrical stimulators the policy requires radiographic evidence of skeletal maturity and demonstration of increased risk for fusion failure as specified (eg, prior failed fusion ≥6 months since last surgery, multilevel fusion, qualifying comorbidities, spondylolisthesis ≥ grade II).

Exclusions and required documentation were clarified in the revision: medical record submissions should include the condition requiring treatment, relevant diagnostic imaging (including evidence of skeletal maturity and, when relevant, presence/absence and grade of spondylolisthesis), relevant surgical history with dates, and the physician's treatment plan. The policy also clarifies that stimulators remain unproven and not medically necessary for indications not listed as covered (including stress fractures).

Use of low‑intensity pulsed ultrasound bone growth stimulators (UBGS) is supported by the policy only for treatment of long‑bone nonunions meeting the specified criteria (for example, gap ≤ 1 cm, persistent fracture line ≥ 3 months, reduced and immobilized fracture, less than 6 months since most recent surgical procedure, non‑pathologic fracture, and skeletal maturity).

The evidence does not support UBGS for other indications such as fresh fractures or routine use in acute fractures. The 2018 NICE guidance cited in the policy explicitly recommends against using LIPUS for fresh fractures at low risk of non‑healing and limits use for other fresh fracture indications to research or special arrangements.

The policy does not endorse the use of invasive or non‑invasive electrical stimulators or ultrasonic stimulators for indications beyond those specifically listed (spinal fusion adjunct in high‑risk patients and UBGS for qualifying long‑bone nonunions). Other clinical uses — including treatment of stress fractures, routine acute fractures, or indications not meeting the policy criteria — are not supported.

NASS provides a conditional recommendation for electrical stimulation as an adjunct in selected acute traumatic spinal fractures for patients at high risk of pseudarthrosis, but this is limited, time‑bound, and requires defined fracture characteristics and monitoring per the guideline. Outside these defined and evidence‑supported indications the policy does not support coverage.

For clarity, the policy states that the use of invasive or non‑invasive electrical bone growth stimulators and ultrasonic bone growth stimulators is unproven and not medically necessary for all other indications not listed as covered (explicitly including stress fractures). This stance is based on insufficient evidence of efficacy and/or safety for those other uses.

Providers should therefore limit requests and documentation to the specific covered indications and required supporting records; use outside those indications is considered not medically necessary by this policy.

Coding and Billing

Electrical Bone Growth Stimulator CPT CodesCPT

20974	Electrical stimulation to aid bone healing; noninvasive (nonoperative)
20975	Electrical stimulation to aid bone healing; invasive (operative)

Ultrasound Bone Growth Stimulator CPT CodesCPT

20979

Low intensity ultrasound stimulation to aid bone healing, noninvasive (nonoperative)

HCPCS CodesHCPCS

E0747	Osteogenesis stimulator, electrical, noninvasive, other than spinal applications
E0748	Osteogenesis stimulator, electrical, noninvasive, spinal applications
E0749	Osteogenesis stimulator, electrical, surgically implanted
E0760	Osteogenesis stimulator, low intensity ultrasound, noninvasive

FDA product codes referencedmixed

LOE	Product code for stimulator, invasive bone growth
LOF	Product code for stimulator, bone growth, non-invasive
LPQ	Product code for ultrasound bone growth stimulators

inv-16: Fracture gap — numeric/value key

Fracture gap<= 1 cm

ContextCriterion applies to Ultrasonic Bone Growth Stimulators for long-bone nonunion

Documentation neededImaging report should specify measured gap size

inv-17: Radiographic persistence duration — >= 3 months

Radiographic persistence duration>= 3 months

MeaningPersistent fracture line without bridging callus present for the specified duration

Provider Actions & Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization requirements follow the member-specific benefit plan. Submit a prior authorization request when seeking coverage for electrical or ultrasonic bone growth stimulators; authorization does not guarantee benefit eligibility — final coverage is determined by the member’s benefit plan and applicable laws.

Prior authorization required per member-specific benefit plan
Include applicable device and procedure codes for reference and reporting (see policy coding section)

Denial Risk

Documentation Risk

When requesting prior authorization for an electrical or ultrasonic stimulator, include clinical documentation that demonstrates the member meets the policy’s clinical criteria. Failure to provide required documentation may result in denial of the request because coverage is based on the member’s specific benefit plan and available medical records.

Background

Bone healing is influenced by multiple factors that determine the rate and likelihood of union. Important determinants include the type of bone involved, the extent of tissue and vascular damage at the injury site, the degree of separation between fracture ends (gap size), the member's overall health and nutritional status, and the absence of local or systemic infection.

The policy requires demonstration of these healing considerations where relevant (for example, documentation of a fracture gap ≤ 1 cm and radiographic persistence of a fracture line for ≥ 3 months when assessing eligibility for ultrasonic stimulation) because these anatomic and physiologic factors materially affect the probability of successful nonoperative healing.

Definitions

inv-29: Electrical Bone Growth Stimulator — device definition (invasive vs external)

DefinitionDevice using electric fields or currents to stimulate bone growth; may be implantable (invasive) or worn externally (non-invasive)

Invasive (implantable)Implantable current generator placed surgically with electrodes at the targeted fusion site; usually implanted at time of spinal fusion

Non-Invasive (external)External power source generating weak electrical current via pulsed electromagnetic fields, capacitive coupling, or combined magnetic fields

inv-30: Ultrasonic Bone Growth Stimulator — LIPUS device definition and components

DefinitionNon-invasive device that emits low-intensity pulsed ultrasound (LIPUS) to accelerate bone repair

Components